Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

CONCLUSIONS: Belzutifan continued to show robust activity and manageable safety in VHL disease-associated pNETs.PMID:38393723 | DOI:10.1158/1078-0432.CCR-23-2592

Source: Cell Research - February 23, 2024 Category: Cytology Authors: Tobias Else Eric Jonasch Othon Lliopoulos Kathryn E Beckermann Vivek Narayan Benjamin L Maughan Stephane Oudard Jodi K Maranchie Ane B Iversen Cynthia Muller Goldberg Wei Fu Rodolfo F Perini Yanfang Liu W Marston Linehan Ramaprasad Srinivasan Source Type: research